Neurizon NUZ-001 OLE study demonstrates long-term safety, efficacy signals
HotCopper sat down with Neurizon Therapeutics MD Michael Thurn to discuss the clinical-stage biotech company's latest NUZ-001 OLE study.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
RAT | buy back | 20/10/23 | 30 | 3.2K | |||
|
|||||||
RAT | Ann: REMOVAL FROM OFFICIAL LIST | 10:13 | 0 | 1.2K | |||
|
|||||||
RAT | Ann: Letter to Shareholders | 22/12/09 | 0 | 1.3K | |||
|
|||||||
RAT | Ann: Company Update | 21/12/09 | 0 | 1.2K | |||
|
|||||||
RAT | Ann: Letter to Shareholders - Winding up of the C | 16:25 | 0 | 1.2K | |||
|
|||||||
RAT | Ann: Trust Update | 08/10/09 | 0 | 1.2K | |||
|
|||||||
RAT | Ann: Letter to Shareholders | 15/09/09 | 0 | 1.0K | |||
|
|||||||
RAT | Ann: Letter to Shareholders | 04/09/09 | 0 | 1.0K | |||
|
See All Discussions